PAVmed (PAVM) Cost of Revenue (2021 - 2026)

PAVmed has reported Cost of Revenue for 6 years, with the latest figure at $122000.0 in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 197.56% year-over-year to $122000.0 in Q2 2026; TTM through Jun 2026 was $303000.0, a 83.08% decrease from a year earlier, with the FY2025 full-year figure at $218000.0, down 95.5% from the prior year.
• Cost of Revenue was $122000.0 for Q2 2026 at PAVmed, up from $85000.0 in the prior quarter.
• The five-year high for Cost of Revenue was $1.8 million in Q3 2023, with the low at $36000.0 in Q3 2024.
• Average Cost of Revenue over 5 years is $866687.5, with a median of $857500.0 recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 1029.17% in 2022, then tumbled 97.94% in 2025.
• Over 5 years, Cost of Revenue stood at $1.6 million in 2022, then decreased by 0.43% to $1.6 million in 2023, then sank by 97.02% to $48000.0 in 2024, then soared by 77.08% to $85000.0 in 2025, then jumped by 43.53% to $122000.0 in 2026.
• The last three Cost of Revenue figures came in at $122000.0 (Q2 2026), $85000.0 (Q4 2025), and $55000.0 (Q3 2025), per Business Quant data.